Efficacy of orally administered fluralaner (Bravecto TM ) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs

Table 3 Hair re-growth on dogs with generalized demodectic mange after treatment with Bravecto™ or Advocate®

Study day	Estimated percent hair re-growth ^a
	Bravecto ^™b (number of dogs/number of dogs per group)			Advocate® ^c (number of dogs/number of dogs per group)
	0-50%	50-90%	>90%	0-50%	50-90%	>90%
28	3/8	1/8	4/8	6/8	1/8	1/8
56	0/8	1/8	7/8	0/8	1/8	7/8
84	0/8	1/8	7/8	0/7^d	1/7^d	6/7^d

^aPercentage hair re-growth defined as estimated percentage of hair cover growth compared to baseline total hairless area as assessed prior to veterinary product administration.
^bDogs were treated once orally on Day 0.
^cDogs were treated topically on Day 0, on Day 28 and again on Day 56. Hair assessments were performed before treatment.
^dOn day 59 one dog had to be euthanized due to the presence of a malign tumour in the stomach.